Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECAMYLAMINE HYDROCHLORIDE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
FDA: Management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension.,Off-label: Treatment of Tourette syndrome, tics, and as an adjunct in smoking cessation.
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
250 mg orally twice daily
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily hepatic with some renal excretion. Metabolized by cytochrome P450 enzymes, likely multiple isoforms, though specific enzymes not fully characterized.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 0-20% bound, primarily to albumin and alpha-1 acid glycoprotein; low binding is clinically insignificant.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Vd approximately 1-2 L/kg; extensive tissue distribution indicates high penetration into tissues.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: approximately 20-50% due to incomplete absorption and first-pass metabolism.
70-90% (oral); 100% (IV).
Contraindicated in patients with renal insufficiency (e GFR <30 m L/min). For mild to moderate impairment, reduce dose by 50% and monitor closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% and titrate slowly.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for use in children due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 2.5 mg once daily; increase slowly with careful monitoring due to increased sensitivity to hypotensive effects and higher risk of adverse effects.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause orthostatic hypotension, syncope, and impaired mental alertness.,Caution in patients with poor renal function, prostatic hypertrophy, or pyloric stenosis.,Risk of rebound hypertension upon abrupt discontinuation.,Mecamylamine may precipitate urinary retention in patients with bladder dysfunction.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to mecamylamine or any component.,Coronary artery disease (risk of precipitation of angina).,Recent myocardial infarction.,Glaucoma (may increase intraocular pressure).,Uremia.,Concurrent use with ganglionic blocking agents.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid excessive alcohol intake as it may potentiate hypotensive effects. No specific food restrictions beyond maintaining a balanced diet.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of teratogenicity due to ganglionic blockade; avoid unless essential. Second/third trimester: may cause fetal hypotension, hypoxia, meconium aspiration, and neonatal respiratory depression due to maternal hypotension and reduced uterine blood flow. Neonatal withdrawal syndrome reported with chronic use.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in breast milk; M/P ratio not established. Risk of infant ganglionic blockade (hypotension, constipation, urinary retention). Contraindicated in breastfeeding due to potential for serious adverse effects.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No established pregnancy-specific dose adjustments. Use lowest effective dose due to volume of distribution and clearance changes (increased plasma volume, renal clearance). Monitor closely for hypotension; consider dose reduction if significant maternal hypotension occurs.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Mecamylamine is a non-competitive antagonist of nicotinic acetylcholine receptors, used primarily for hypertension. It does not affect parasympathetic ganglia at therapeutic doses. Caution in patients with renal impairment as drug accumulation occurs. Avoid use in patients with glaucoma or pyloric stenosis due to anticholinergic effects.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not skip doses or double up on missed doses.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it can cause dizziness or blurred vision.,Report any signs of slow heart rate, fainting, difficulty urinating, or blurred vision to your healthcare provider immediately.,Do not stop taking this medication abruptly; your blood pressure may rise rapidly.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
"Mecamylamine, a noncompetitive nicotinic acetylcholine receptor antagonist used for hypertension, potentiates the vasodilatory effects of Manidipine, a dihydropyridine calcium channel blocker, by reducing sympathetic reflex responses that normally counteract calcium channel blocker-induced hypotension. This additive hypotensive effect can lead to severe hypotension, dizziness, syncope, and increased risk of falls or cardiovascular events, particularly in elderly patients or those with volume depletion."
"Mecamylamine, a noncompetitive antagonist of nicotinic acetylcholine receptors, blocks sympathetic ganglionic transmission, leading to reduced catecholamine release and hypotension. Phentolamine, a nonselective alpha-adrenergic antagonist, further inhibits vasoconstriction mediated by norepinephrine. Concurrent use results in additive hypotensive effects, increasing the risk of severe hypotension, orthostatic dizziness, and syncope, particularly during initial dosing or dose escalation."
"Mecamylamine, a ganglionic blocker, antagonizes nicotinic acetylcholine receptors, leading to sympatholytic effects. Nabilone, a synthetic cannabinoid, can increase heart rate via central sympathetic activation. The interaction results in Mecamylamine augmenting the tachycardic effects of Nabilone, potentially causing excessive heart rate elevation and risk of cardiac stress."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECAMYLAMINE HYDROCHLORIDE vs ALDOCLOR-250, answered by our medical review team.
MECAMYLAMINE HYDROCHLORIDE is a Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECAMYLAMINE HYDROCHLORIDE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECAMYLAMINE HYDROCHLORIDE is: Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECAMYLAMINE HYDROCHLORIDE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECAMYLAMINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of ter. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.